Efficacy and safety of BAFF/APRIL dual antagonists in IgA nephropathy: a systematic review and meta-analysis of randomized controlled trials
Zhonghua Tian, Yalin Yang, Mingchun Huang, Zhie Fang, Jixiong Mei, Yunyi Li, Ling Tang, Yanyan Li, Yuxia Li · 2025
Read Efficacy and safety of BAFF/APRIL dual antagonists in IgA nephropathy: a systematic review and meta-analysis of randomized controlled trials by Zhonghua Tian, Yalin Yang, Mingchun Huang, Zhie Fang, Jixiong Mei, Yunyi Li, Ling Tang, Yanyan Li, Yuxia Li (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12821315.txt.
Description
Zhonghua Tian and co-authors pool trial evidence on a dual-action drug class for a common kidney disease. Their 2025 review covers IgA nephropathy, the world's most frequent primary kidney filter disease, where two B-cell signals called BAFF and APRIL run high and track with severity.
Three phase two trials with two hundred sixty-three patients entered the pool. Drugs blocking both signals cut urine protein far more than control care and slowed the loss of kidney function. They also lowered the faulty antibody at the disease's root. The costs were more injection site reactions and broad drops in protective antibodies, which may weaken immunity. The authors urge caution and larger trials before firm claims.
Catalog record
| CREATOR | Zhonghua Tian, Yalin Yang, Mingchun Huang, Zhie Fang, Jixiong Mei, Yunyi Li, Ling Tang, Yanyan Li, Yuxia Li |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 53 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |